Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO – Get Free Report) reached a new 52-week low on Monday . The stock traded as low as $0.40 and last traded at $0.41, with a volume of 3791105 shares trading hands. The stock had previously closed at $0.43.
Northwest Biotherapeutics Stock Down 3.9 %
The firm has a market capitalization of $503.98 million, a price-to-earnings ratio of -6.10 and a beta of -0.57. The business has a 50-day moving average of $0.46 and a two-hundred day moving average of $0.54.
Northwest Biotherapeutics (OTCMKTS:NWBO – Get Free Report) last announced its quarterly earnings data on Friday, May 10th. The biotechnology company reported ($0.02) earnings per share for the quarter. The firm had revenue of $0.28 million during the quarter.
Northwest Biotherapeutics Company Profile
Northwest Biotherapeutics, Inc, a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer.
Featured Stories
- Five stocks we like better than Northwest Biotherapeutics
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- These Top 3 Banks Raise Dividends After Passing Fed Stress Test
- Consumer Staples Stocks, Explained
- Hitch a Ride with Lyft Stock for Double-Digit Gains in 2nd Half
- Breakout Stocks: What They Are and How to Identify Them
- Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
Receive News & Ratings for Northwest Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Northwest Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
